Surgery Partners Stock Price and Value Analysis

Surgery Partners (NasdaqGS:SGRY) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Surgery Partners to reach your target.

Target type

SGRY Free Cash Flow Trend

Free Cash Flow trendline for SGRY
Free Cash Flow trendline for Surgery Partners
CSV

Based on historical returns, we believe that Surgery Partners can grow its free cash at a rate of about 2%. That's positive!

AdvantagesDisadvantagesNeutral
None.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the SGRY Numbers

SGRY Price
(Surgery Partners stock price per share)
$26.78
[?] SGRY Fair Price
(based on intrinsic value)
$13.09
[?] SGRY Safety Price (based on a variable margin of safety) $7.85
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Medical Care Facilities stocks
[?] Free Cash Flow Jitter 40%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 8,951,583 shares shorted. With 59,422,641 shares available for purchase and an average trading volume over the past 10 trading days of 4,629,960, it would take at least 1.9 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2013 1638833 44.9
2014 1638833 16
2015 1638833 69.4
2016 1638833 104
2018 1638833 120
2019 1638833 90.8
2020 1638833 201
2021 1638833 36.5
2022 1638833 99.9
2023 1638833 225
2024 1638833 228
2025 1638833 195

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 2 fiscal years from 2013 to 2025 with positive net income, operating cash flow totaled $210 million against net income of $10.9 million, or 19.27 times. Net income was negative in 10 of the 12 years, and those years are left out of the ratio.

In 2025, net income was -$77.9 million and operating cash flow was $274 million, so no ratio is shown for that year.

In 2025, capital expenditures were $78.7 million, 28.7% of operating cash flow of $274 million, which leaves an estimated $196 million after capex. Across the 12 years with reported capex, it averaged 33.2% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2013 -9.1 49.1 4.2 n/a
2014 -65.9 21.9 7.7 n/a
2015 1.4 84.5 33.4 59.12
2016 9.5 125 39.1 13.25
2018 -206 145 39.8 n/a
2019 -74.8 130 73.6 n/a
2020 -116 247 42.9 n/a
2021 -70.9 87.1 57.6 n/a
2022 -54.6 159 80.6 n/a
2023 -11.9 294 88.8 n/a
2024 -168 300 90.4 n/a
2025 -77.9 274 78.7 n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $285 million in 2013 and $3,309 million in 2025, a compound annual growth rate of 22.7% over 12 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 6.2% from 2024 to 2025.

Our estimated free cash flow was $195 million in 2025, 5.9% of revenue. In 2013 the estimated margin was 15.8%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2013 285 44.9 15.8%
2014 403 16 4.0%
2015 960 69.4 7.2%
2016 1,145 104 9.1%
2018 1,772 120 6.8%
2019 1,831 90.8 5.0%
2020 1,860 201 10.8%
2021 2,225 36.5 1.6%
2022 2,539 99.9 3.9%
2023 2,743 225 8.2%
2024 3,114 228 7.3%
2025 3,309 195 5.9%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $240 million against total liabilities of $4,593 million, or 5.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 56.6% of total assets in 2025, compared with 88.1% in 2014, a decrease of 31.5 percentage points.

Stockholders equity was $3,131 million in 2025, compared with $29.5 million in 2014, a rise of 10501.6%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 2.7% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2014 1,859 74.9 1,637 29.5
2015 2,104 57.9 1,623 298
2016 2,305 69.7 1,800 325
2017 4,623 175 2,987 1,337
2018 4,676 184 3,251 1,099
2019 5,019 92.7 3,715 983
2020 5,413 318 4,224 882
2021 6,118 390 3,818 1,970
2022 6,682 283 3,399 2,941
2023 6,877 196 3,515 3,035
2024 7,890 270 4,255 3,196
2025 8,120 240 4,593 3,131

Price Versus Our Estimated Value

Our fair value estimate for Surgery Partners is $13.09, below its current price of $26.78.

Free cash flow was positive in all 12 fiscal years we have for Surgery Partners under its current SEC filer.

Surgery Partners's average free cash flow rose sharply, from $43.4 million in its earliest three years to $216 million in its latest three.

Free cash flow is volatile from year to year, with a variability measure of 40%.

Our value investing guide explains how to test these numbers against the filings themselves.

No dividend yield is recorded for Surgery Partners in our data.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Medical Care Facilities industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Care Facilities industry, the ones closest in market capitalization to Surgery Partners, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Surgery Partners (SGRY) 3,505 - - - 105% above
Progyny (PGNY) 2,630 32.8 - - 409% above
Healthcare Services Group (HCSG) 1,667 16.7 - 4.0% 17% below
U.S. Physical Therapy (USPH) 1,432 - 1.9% 3.0% 1% below
DaVita (DVA) 10,129 12.2 - 14.7% 57% below
Universal Health Services (UHS) 10,345 7.5 0.5% 13.7% 71% below
Encompass Health Corporation (EHC) 13,114 21.4 0.6% - 438% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1638833.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: SGRY annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in SGRY

Does Surgery Partners have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: SGRY

This example shows how we apply the Trendshare checklist to SGRY: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 26.78
    • Market cap: $3.5B
    • EPS: -0.67
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.